64,813 Shares in Revolution Medicines, Inc. $RVMD Bought by Freestone Grove Partners LP

Freestone Grove Partners LP purchased a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 64,813 shares of the company’s stock, valued at approximately $12,138,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of RVMD. Vanguard Group Inc. boosted its holdings in Revolution Medicines by 6.7% during the 4th quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock valued at $1,331,739,000 after acquiring an additional 1,056,792 shares during the period. State of Wyoming bought a new position in Revolution Medicines during the 2nd quarter worth approximately $1,769,000. Handelsbanken Fonder AB increased its stake in Revolution Medicines by 243.6% in the 2nd quarter. Handelsbanken Fonder AB now owns 212,275 shares of the company’s stock worth $39,755,000 after purchasing an additional 150,500 shares during the period. Eagle Health Investments LP purchased a new position in Revolution Medicines in the 4th quarter worth approximately $9,231,000. Finally, Assenagon Asset Management S.A. bought a new stake in Revolution Medicines in the second quarter valued at approximately $37,547,000. 94.34% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, COO Margaret A. Horn sold 60,400 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $160.17, for a total transaction of $9,674,268.00. Following the completion of the sale, the chief operating officer owned 158,222 shares of the company’s stock, valued at $25,342,417.74. This represents a 27.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Stephen Michael Kelsey sold 4,175 shares of the stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $156.12, for a total transaction of $651,801.00. Following the completion of the transaction, the insider owned 291,876 shares in the company, valued at $45,567,681.12. This trade represents a 1.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 212,497 shares of company stock valued at $38,206,486. 7.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

RVMD has been the subject of a number of analyst reports. Wedbush increased their price objective on Revolution Medicines from $201.00 to $225.00 and gave the company an “outperform” rating in a research note on Thursday. TD Cowen upgraded Revolution Medicines to a “strong-buy” rating in a research note on Monday. Sanford C. Bernstein lifted their target price on Revolution Medicines from $151.00 to $179.00 and gave the stock a “market perform” rating in a report on Friday, August 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a research note on Friday, July 17th. Finally, Royal Bank Of Canada upped their price target on Revolution Medicines from $203.00 to $251.00 and gave the company an “outperform” rating in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $193.28.

Revolution Medicines Stock Performance

RVMD stock opened at $221.15 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. Revolution Medicines, Inc. has a 1 year low of $37.56 and a 1 year high of $224.31. The company has a market cap of $47.40 billion, a P/E ratio of -25.07 and a beta of 1.39. The stock’s fifty day moving average price is $192.43 and its 200-day moving average price is $148.17.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter in the prior year, the firm posted ($1.31) earnings per share. On average, equities analysts forecast that Revolution Medicines, Inc. will post -8.82 earnings per share for the current year.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Landmark FDA approval: RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, addressing a disease with limited treatment options and potentially validating Revolution Medicines’ RAS/MAPK drug-development platform. FDA approval announcement
• Positive Sentiment: Commercial opportunity expands: Analysts said the RASONQUE label creates a sizable opportunity, while RBC viewed the company’s planned launch as rapid. Management’s discussion also emphasized the approval’s implications for broader RAS-driven cancer treatment and future indications. Rasonque label expansion analysis
• Positive Sentiment: Higher analyst targets: Truist raised its price target from $231 to $239 and maintained a Buy rating, while Wedbush increased its target from $201 to $225 and kept an Outperform rating. These revisions reflect improved confidence following the approval. Analyst price target changes
• Neutral Sentiment: Pricing and launch execution will matter: Revolution Medicines priced RASONQUE at approximately $39,800 per month. The price supports substantial revenue potential, but payer coverage, patient access and real-world adoption could influence how quickly the approval translates into sales. Rasonque pricing article
• Negative Sentiment: Insider selling and ongoing losses remain risks: Insider Mark Goldsmith sold 80,000 shares for roughly $16.7 million, reducing his holdings by about 23%. Revolution Medicines also remains unprofitable, and its latest quarterly loss exceeded analyst expectations, so the stock’s valuation depends heavily on successful commercialization and pipeline progress. Insider sale report

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.